Perspectum secures £15.6m in Series C funding led by Oppenheimer to scale its US operations and product pipeline.
Oppenheimer led the Series C financing, which will support US expansion and the development of new diagnostic tools.
Perspectum develops advanced medical imaging and diagnostic software to assist clinicians in identifying and monitoring metabolic conditions and cancer. The firm operates globally with bases in the UK, the US, Portugal, and Singapore.
Perspectum has secured £15.6m in a Series C funding round led by Oppenheimer. The capital injection will enable the medical technology firm to expand its footprint in the US and accelerate product development for multiorgan pathologies and oncology.
The business provides software that enhances standard magnetic resonance imaging machines to measure organ health with greater precision. Its flagship tool, LiverMultiScan, has gained traction across US hospitals following expanded Medicare coverage and established reimbursement codes.
This latest investment follows previous capital raises that bring the company total funding to approximately $140m since inception. The firm intends to use the proceeds to support clinical research, validation, and commercial adoption of its diagnostic platform.
From the founder
"The second Series C second close further supports deployment, development and validation of our platform-based product portfolio targeted for clinical research and clinical use,"
Rajarshi Banerjee
CEO at Perspectum
Use of funds
- 01Continue product development
- 02Expand into international markets
Investors
Categories
About the company
Perspectum
Perspectum builds medical imaging software that uses artificial intelligence to improve the diagnosis of chronic diseases and cancer.